Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company's potential treatment for a rare disease. The FDA's Decision on BHVN's Drug Candidate The FDA agreed to review BHVN's ...

Bernstein lowered the firm’s price target on Biohaven (BHVN) to $57 from $73 and keeps an Outperform rating on the shares. The firm notes the company’s Q4 update included mixed degrader Phase ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed ...

The last time I wrote about Biohaven (NYSE:BHVN) it was with respect to a Seeking Alpha article entitled "Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst." ...

Biohaven has a 52-week low of $26.80 and a 52-week high of $62.21. Biohaven ( NYSE:BHVN – Get Free Report ) last announced its earnings results on Monday, March 3rd.

Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker than expected quarterly earnings.The company traded as low as $34.27 and ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia, or SCA ...

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...